English (UK)
中文版
Dr Lihua Zheng
AnHeart Therapeutics is an oncology-focused clinical stage biopharmaceutical company headquartered in Hangzhou, China with offices in Beijing, Shanghai and New York. The company’s pipeline consists of three clinical stage assets: Taletrectinib, a next-gen ROS1 and NTRK inhibitor currently in Phase 2; an mIDH1 inhibitor ready for Phase 2 for low grade glioma, cholangiocarcinoma, AML and other tumors; and an AXL inhibitor in Phase 1 for overcoming resistance in various tumors.
AnHeart Therapeutics
CBO & co-Founder
Linda Zheng
A French PHARMA & cosmetics company
Pierre Fabre Medicament China
Senior Market Access & Health Economics DirectorMin Zhou
Hainan Haiyao, a Chinese public company with stock code of 000566, is established in 1965, mainly focused on some severe diseases such as infection, tumor, digestion system etc.
Hainan Haiyao Co. , Ltd
BD DirectorIvy Zhou
Shenzhen Beimei Pharma is focused in the field of pediatric prescription drugs, and aims to become a new-styled pharmaceutical company integrated with R&D, in-licensing, production and sales. It takes independent R&D and the in-licensing of domestic and international pediatric products as its strategic direction. The current product pipeline covers the respiratory, anti-infection (antibacterial), neuroscience, gastroenterology and others. Beimei Pharma is committed to providing Chinese pediatric patients with convenient, accurate, excellent-taste and high-quality products.
Shenzhen Beimei Pharmaceutical Co. Ltd.
Head of Business DevelopmentKaiqi Zhou
Top medical device company in China focused on cardiovascular, surgical robotics and ten more fields.
Responsive Web Design powered by 